{"id":972,"date":"2014-02-11T11:10:00","date_gmt":"2014-02-11T11:10:00","guid":{"rendered":"https:\/\/www.medinadiscovery.com\/c17-medina-news\/imi-programme-targets-novel-antibiotics\/"},"modified":"2016-08-24T13:24:06","modified_gmt":"2016-08-24T13:24:06","slug":"imi-programme-targets-novel-antibiotics","status":"publish","type":"post","link":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/","title":{"rendered":"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>MEDINA inicia el\u00a0desarrollo\u00a0de su primer\u00a0antibi\u00f3tico\u00a0dentro del consorcio\u00a0europeo\u00a0ENABLE que tiene como objetivo encontrar soluciones\u00a0innovadoras\u00a0en\u00a0la lucha contra enfermedades\u00a0infecciosas.<\/strong><\/p>\n<p style=\"text-align: justify;\">Mas de 30 universidades y empresas europeas, dirigidos por GlaxoSmithKline y la Universidad Uppsala, a\u00fanan esfuerzos dentro de un proyecto llamado ENABLE (<u>E<\/u>uropean Gram\u00a0<u>N<\/u>egative\u00a0<u>A<\/u>nti<u>b<\/u>acterial\u00a0<u>E<\/u>ngine). Tiene 6 a\u00f1os de duraci\u00f3n, esta financiado por el IMI (Innovative Medicines Initiative) y consiste en desarrollar nuevos antibi\u00f3ticos contra pat\u00f3genos Gram.negative. El mundo se enfrenta a una epidemia creciente de resistencia a los antibi\u00f3ticos y sin embargo solo dos nuevos antibi\u00f3ticos fueron tra\u00eddos al mercado en los 30 \u00faltimos a\u00f1os. El descubrimiento y el desarrollo de nuevos antibi\u00f3ticos es esencial para mantener los avances m\u00e9dicos pero supone una serie de retos a nivel cient\u00edfico, cl\u00ednico y financiero, particularmente para los antibi\u00f3ticos activos sobre bacteria Gram-negative como\u00a0<em>E.coli<\/em>. Este tipo de bacterias tiene barreras muy efectivas contra los f\u00e1rmacos, dificultando el el tratamiento, la resistencia probable y los costes de desarrollo \u00a0y riesgos altos. Adem\u00e1s, todo antibi\u00f3tico tra\u00eddo al mercado se debe de usar con mucha precauci\u00f3n para retrasar su resistencia lo cual a\u00f1ade nuevos retos financieros a la hora de recuperar la inversi\u00f3n que supuso su\u00a0desarrollo.<\/p>\n<p style=\"text-align: justify;\"><i>V\u00eda<\/i><em>\u00a0Publica &#8211; privada<\/em><\/p>\n<p style=\"text-align: justify;\">Como respuesta a dichas barreras en el desarrollo de nuevos antibi\u00f3ticos, el IMI, fruto de una colaboraci\u00f3n entre la Comisi\u00f3n \u00a0Europea y las mayores empresas farmac\u00e9uticas (a trav\u00e9s de EFPIA, la Federaci\u00f3n Europea des las Industrias Farmac\u00e9uticas y Asociaciones), lanzaron una serie de proyectos llamados &#8220;New Drugs for Bad Bugs&#8221; (ND4BB), con el prop\u00f3sito de canalizar el desarrollo y el uso eficaz de nuevos antibi\u00f3ticos.<\/p>\n<p style=\"text-align: justify;\">El proyecto ENABLE, el tercero dentro de la serie ND4BB, abarca 13 pa\u00edses y re\u00fane 32 socios y forma una plataforma de descubrimiento de f\u00e1rmacos antibacterianos \u00a0para el avance de los programas de investigaci\u00f3n en fase de descubrimiento y de Fase cl\u00ednica 1. Un porfolio preliminar de programas sera difundido fuera del consorcio para crear una fuente de informaci\u00f3n completa, incluyendo como m\u00e1xima meta la entrega de al menos un candidato antibacteriano contra infecciones Gram-negative en Fase 2 para 2019.<\/p>\n<p style=\"text-align: justify;\">Este proyecto de iniciativa e inversi\u00f3n publica-privada a trav\u00e9s del IMI refleja el cambio que experimenta el desarrollo de nuevos f\u00e1rmacos de alto riesgo como los antibi\u00f3ticos, y tiene como misi\u00f3n movilizar la pericia por parte de las universidades y la industria en Europa intentando alcanzar las metas globales. A la vez, posiciona Europa a la vanguardia de la investigaci\u00f3n colaborativa entre la industria y el sector acad\u00e9mico en temas de salud publica.<\/p>\n<p style=\"text-align: justify;\">\u201cMEDINA aporta el proyecto una de las nuevas mol\u00e9culas antibi\u00f3ticas que ser\u00e1n desarrolladas \u00a0dentro de la colaboraci\u00f3n. Nuestra participaci\u00f3n en este programa es una oportunidad considerable para desarrollar conjuntamente los compuestos mas avanzados \u00a0que tenemos en proyecto.\u201d comenta Olga Genilloud, Directora Cient\u00edfica de MEDINA.<\/p>\n<p style=\"text-align: justify;\"><a href=\"http:\/\/www.imi.europa.eu\/\">\u00a0<\/a><a href=\"http:\/\/www.imi.europa.eu\/\">http:\/\/www.imi.europa.eu\/<\/a><a href=\"http:\/\/www.imi.europa.eu\/\">\u00a0<\/a><\/p>\n<p style=\"text-align: justify;\">\u00a0\u201cPlan de acci\u00f3n contra las amenazas de la resistencia antimicrobiana\u201d<\/p>\n<p style=\"text-align: justify;\"><a href=\"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2014\/02\/communication_amr_2011_748_en.pdf\">\u00a0<\/a><a href=\"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2014\/02\/communication_amr_2011_748_en.pdf\">http:\/\/ec.europa.eu\/dgs\/health_consumer\/docs\/communication_amr_2011_748_en.pdf<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mas de 30 universidades y empresas europeas, dirigidos por GlaxoSmithKline y la Universidad Uppsala, a\u00fanan esfuerzos dentro de un proyecto llamado ENABLE (European Gram Negative Antibacterial Engine). Tiene 6 a\u00f1os de duraci\u00f3n, esta financiado por el IMI&#8230;<\/p>\n","protected":false},"author":101011,"featured_media":6159,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[118,85],"tags":[],"class_list":["post-972","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-archivo-noticias-medina","category-noticias-medina"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos - Fundaci\u00f3n MEDINA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos - Fundaci\u00f3n MEDINA\" \/>\n<meta property=\"og:description\" content=\"Mas de 30 universidades y empresas europeas, dirigidos por GlaxoSmithKline y la Universidad Uppsala, a\u00fanan esfuerzos dentro de un proyecto llamado ENABLE (European Gram Negative Antibacterial Engine). Tiene 6 a\u00f1os de duraci\u00f3n, esta financiado por el IMI...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/\" \/>\n<meta property=\"og:site_name\" content=\"Fundaci\u00f3n MEDINA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MEDINADiscovery\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-02-11T11:10:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2016-08-24T13:24:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2016\/07\/iminews.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"334\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DeletedUser\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@MedinaDiscovery\" \/>\n<meta name=\"twitter:site\" content=\"@MedinaDiscovery\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"DeletedUser\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/\"},\"author\":{\"name\":\"DeletedUser\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#\\\/schema\\\/person\\\/62145ed43c23f69b11b09c5bf71dd5cf\"},\"headline\":\"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos\",\"datePublished\":\"2014-02-11T11:10:00+00:00\",\"dateModified\":\"2016-08-24T13:24:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/\"},\"wordCount\":554,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medinadiscovery.com\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/iminews.jpg\",\"articleSection\":[\"ARCHIVO NOTICIAS MEDINA\",\"Noticias Medina\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/\",\"url\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/\",\"name\":\"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos - Fundaci\u00f3n MEDINA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medinadiscovery.com\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/iminews.jpg\",\"datePublished\":\"2014-02-11T11:10:00+00:00\",\"dateModified\":\"2016-08-24T13:24:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.medinadiscovery.com\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/iminews.jpg\",\"contentUrl\":\"https:\\\/\\\/www.medinadiscovery.com\\\/wp-content\\\/uploads\\\/2016\\\/07\\\/iminews.jpg\",\"width\":900,\"height\":334},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/imi-programme-targets-novel-antibiotics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/\",\"name\":\"Fundaci\u00f3n MEDINA\",\"description\":\"Our mission on drug discovery and pharma research\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#organization\",\"name\":\"Fundaci\u00f3n MEDINA\",\"url\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.medinadiscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/logo_medina.png\",\"contentUrl\":\"https:\\\/\\\/www.medinadiscovery.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/logo_medina.png\",\"width\":1747,\"height\":456,\"caption\":\"Fundaci\u00f3n MEDINA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/MEDINADiscovery\\\/\",\"https:\\\/\\\/x.com\\\/MedinaDiscovery\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/#\\\/schema\\\/person\\\/62145ed43c23f69b11b09c5bf71dd5cf\",\"name\":\"DeletedUser\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/27a206f94337bd11b6dbcdc5eb6a906a75d62be00806e2a32f4551b9a16acccb?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/27a206f94337bd11b6dbcdc5eb6a906a75d62be00806e2a32f4551b9a16acccb?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/27a206f94337bd11b6dbcdc5eb6a906a75d62be00806e2a32f4551b9a16acccb?s=96&d=mm&r=g\",\"caption\":\"DeletedUser\"},\"url\":\"https:\\\/\\\/www.medinadiscovery.com\\\/es\\\/author\\\/deleteduser\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos - Fundaci\u00f3n MEDINA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/","og_locale":"es_ES","og_type":"article","og_title":"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos - Fundaci\u00f3n MEDINA","og_description":"Mas de 30 universidades y empresas europeas, dirigidos por GlaxoSmithKline y la Universidad Uppsala, a\u00fanan esfuerzos dentro de un proyecto llamado ENABLE (European Gram Negative Antibacterial Engine). Tiene 6 a\u00f1os de duraci\u00f3n, esta financiado por el IMI...","og_url":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/","og_site_name":"Fundaci\u00f3n MEDINA","article_publisher":"https:\/\/www.facebook.com\/MEDINADiscovery\/","article_published_time":"2014-02-11T11:10:00+00:00","article_modified_time":"2016-08-24T13:24:06+00:00","og_image":[{"width":900,"height":334,"url":"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2016\/07\/iminews.jpg","type":"image\/jpeg"}],"author":"DeletedUser","twitter_card":"summary_large_image","twitter_creator":"@MedinaDiscovery","twitter_site":"@MedinaDiscovery","twitter_misc":{"Escrito por":"DeletedUser","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/#article","isPartOf":{"@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/"},"author":{"name":"DeletedUser","@id":"https:\/\/www.medinadiscovery.com\/es\/#\/schema\/person\/62145ed43c23f69b11b09c5bf71dd5cf"},"headline":"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos","datePublished":"2014-02-11T11:10:00+00:00","dateModified":"2016-08-24T13:24:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/"},"wordCount":554,"commentCount":0,"publisher":{"@id":"https:\/\/www.medinadiscovery.com\/es\/#organization"},"image":{"@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2016\/07\/iminews.jpg","articleSection":["ARCHIVO NOTICIAS MEDINA","Noticias Medina"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/","url":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/","name":"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos - Fundaci\u00f3n MEDINA","isPartOf":{"@id":"https:\/\/www.medinadiscovery.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/#primaryimage"},"image":{"@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2016\/07\/iminews.jpg","datePublished":"2014-02-11T11:10:00+00:00","dateModified":"2016-08-24T13:24:06+00:00","breadcrumb":{"@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/#primaryimage","url":"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2016\/07\/iminews.jpg","contentUrl":"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2016\/07\/iminews.jpg","width":900,"height":334},{"@type":"BreadcrumbList","@id":"https:\/\/www.medinadiscovery.com\/es\/imi-programme-targets-novel-antibiotics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.medinadiscovery.com\/es\/"},{"@type":"ListItem","position":2,"name":"\u25aa ENABLE: Programa europeo de 85 milliones de \u20ac y 30 colaboradores, investigando nuevos antibioticos"}]},{"@type":"WebSite","@id":"https:\/\/www.medinadiscovery.com\/es\/#website","url":"https:\/\/www.medinadiscovery.com\/es\/","name":"Fundaci\u00f3n MEDINA","description":"Our mission on drug discovery and pharma research","publisher":{"@id":"https:\/\/www.medinadiscovery.com\/es\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.medinadiscovery.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/www.medinadiscovery.com\/es\/#organization","name":"Fundaci\u00f3n MEDINA","url":"https:\/\/www.medinadiscovery.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.medinadiscovery.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2025\/06\/logo_medina.png","contentUrl":"https:\/\/www.medinadiscovery.com\/wp-content\/uploads\/2025\/06\/logo_medina.png","width":1747,"height":456,"caption":"Fundaci\u00f3n MEDINA"},"image":{"@id":"https:\/\/www.medinadiscovery.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MEDINADiscovery\/","https:\/\/x.com\/MedinaDiscovery"]},{"@type":"Person","@id":"https:\/\/www.medinadiscovery.com\/es\/#\/schema\/person\/62145ed43c23f69b11b09c5bf71dd5cf","name":"DeletedUser","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/27a206f94337bd11b6dbcdc5eb6a906a75d62be00806e2a32f4551b9a16acccb?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/27a206f94337bd11b6dbcdc5eb6a906a75d62be00806e2a32f4551b9a16acccb?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27a206f94337bd11b6dbcdc5eb6a906a75d62be00806e2a32f4551b9a16acccb?s=96&d=mm&r=g","caption":"DeletedUser"},"url":"https:\/\/www.medinadiscovery.com\/es\/author\/deleteduser\/"}]}},"_links":{"self":[{"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/posts\/972","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/users\/101011"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/comments?post=972"}],"version-history":[{"count":21,"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/posts\/972\/revisions"}],"predecessor-version":[{"id":6638,"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/posts\/972\/revisions\/6638"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/media\/6159"}],"wp:attachment":[{"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/media?parent=972"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/categories?post=972"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medinadiscovery.com\/es\/wp-json\/wp\/v2\/tags?post=972"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}